Stealth Bio­Ther­a­peu­tics CEO dis­cuss­es sur­prise ad­comm sup­port for ul­tra-rare dis­ease drug

This week, Stealth Bio­Ther­a­peu­tics CEO Ree­nie Mc­Carthy faced a seem­ing­ly in­sur­mount­able road­block with the com­pa­ny’s drug for the ul­tra-rare, fa­tal mi­to­chon­dr­i­al dis­ease Barth syn­drome. FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER